A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.
Saved in:
| Title: | A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. |
|---|---|
| Authors: | Baba K; Department of Oncology and General Medicine, IMSUT Hospital, the Institute of Medical Science Hospital, the University of Tokyo, Tokyo, Japan., Suzuki N; Department of Gastroenterology Graduate School of Medicine, University of Tokyo, Tokyo, Japan., Imamura CK; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan., Booka E; Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan., Takeuchi M; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Takahari D; Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Kawakami T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Kawakubo H; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Kitagawa C; Medical Oncology and Respiratory Medicine, NHO Nagoya Medical Center, Aichi, Japan., Kono Y; Department of Gastroenterology and Hepatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan., Ogura K; Department of Gastroenterology, Tokyo Metropolitan Police Hospital, Tokyo, Japan., Kito Y; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan., Saito K; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan., Yamamoto S; Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan., Takeuchi H; Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan., Kudo T; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Mizukami T; Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan., Yamaguchi T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Saito K; Department of Medical Oncology, Mie University Hospital, Mie, Japan., Tanoue K; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Baba E; Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Nagashima K; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan., Boku N; Department of Oncology and General Medicine, IMSUT Hospital, the Institute of Medical Science Hospital, the University of Tokyo, Tokyo, Japan. nboku@ims.u-tokyo.ac.jp. |
| Source: | BMC cancer [BMC Cancer] 2025 Apr 12; Vol. 25 (1), pp. 675. Date of Electronic Publication: 2025 Apr 12. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-025-14084-1 |
